Selank

Russian anxiolytic in the Tuftsin family - calms without sedation, without the dependence profile of benzodiazepines.

Approved in RussiaResearch chemical (West)IntranasalAnxiolytic

Key facts

Common routesIntranasal, SC

Half-lifeShort / 2–4 h effect

Typical range200–300 mcg

Summary

Selank is a synthetic heptapeptide derived from Tuftsin, an endogenous immunomodulatory tetrapeptide. A Pro-Gly-Pro extension at the C-terminus stabilises the molecule against rapid protease degradation. Developed at the Russian Academy of Sciences' Institute of Molecular Genetics; approved in Russia for generalised anxiety disorder.

Anxiolytic without sedation, without dependence, without withdrawal - the clean dividing line against benzodiazepines. Effects last 2–4 hours per dose; intranasal is the fastest route.

Mechanism notes

GABA modulation

Allosterically modulates GABA(A) receptors, increasing their sensitivity to endogenous GABA. Calming effect without the heavy sedation of direct agonists.

Enkephalin stabilisation

Inhibits the enzymes that degrade endogenous enkephalins. Stabilises mood and improves emotional resilience under stress.

BDNF upregulation

Like Semax, Selank upregulates BDNF (brain-derived neurotrophic factor) - supports neuroplasticity and memory consolidation.

Dosing patterns

Situational anxiety (acute)

0.15% solution intranasal, 200–300 mcg (1–2 sprays per nostril) as needed. Onset 5–15 min; ideal before public speaking, travel, social situations.

Daily baseline

200–300 mcg morning for a smoother baseline. No withdrawal on discontinuation, but the effect fades with continuous use - better as a tool than a continuous baseline.

N-Acetyl variant

Some users prefer N-Acetyl Selank for proposed better BBB penetration. Clinical data is on standard Selank; the modification is theoretical.

Evidence snapshot

Approved drug in Russia for generalised anxiety disorder, with clinical history since the 2000s. Western replication is limited to animal studies; the mechanistic basis (GABA modulation, BDNF) is well-characterised.

Clinical data (Russia)

Kozlovskaia 2003, Uchakina 2008 - small RCTs show GAD improvement comparable to medazepam, without sedation or cognitive slowing.

Western data

Limited to animal studies (mouse models for anxiety and depression) confirming the anxiolytic signature. No Western RCTs.

Safety considerations

One of the cleanest safety profiles in the catalogue. Non-sedating, non-addictive, no withdrawal. Main concerns are sourcing quality (sterile sprays, refrigeration) and realistic expectations - Selank smooths, it isn't a stimulant.

Common cautions

Nasal irritation with frequent intranasal use
Metallic taste as drops drip down the throat
Theoretical immune stimulation (Tuftsin family) - autoimmune users should monitor symptoms
Caution combining with benzodiazepines or alcohol - additive sedation possible